Texture-based automated quantitative assessment of regional patterns on initial CT in patients with idiopathic pulmonary fibrosis: Relationship to decline in forced vital capacity

American Journal of Roentgenology

Volumn 207, Issue 5, 2016, Pages 976-983

  Park, Hyo Jung ^a   Lee, Sang Min ^a   Song, Jin Woo ^a   Oh, Sang Young ^a   Kim, Namkug ^a   Seo, Joon Beom ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

CT quantifcation; Disease pattern; Forced vital capacity; Idiopathic pulmonary fbrosis; Texture analysis

Indexed keywords

ADULT; AGED; ARTICLE; AUTOMATION; COMPUTED TOMOGRAPHY SCANNER; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; EMPHYSEMA; FEMALE; FIBROSING ALVEOLITIS; FOLLOW UP; FORCED VITAL CAPACITY; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMAGE DISPLAY; IMAGING SOFTWARE; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; COMPUTER ASSISTED DIAGNOSIS; DIAGNOSTIC IMAGING; MIDDLE AGED; PATHOPHYSIOLOGY; PROCEDURES; VERY ELDERLY; VITAL CAPACITY; X-RAY COMPUTED TOMOGRAPHY;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; MALE; MIDDLE AGED; RADIOGRAPHIC IMAGE INTERPRETATION, COMPUTER-ASSISTED; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; VITAL CAPACITY;

EID: 84992602716     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.16.16054     Document Type: Article

References (33)

1. Raghu G, Collard HR, Egan JJ, et al.; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An offcial ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fbrosis-evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183:788-824
2. Ley B, Elicker BM, Hartman TE, et al. Idiopathic pulmonary fbrosis: CT and risk of death. Radiology 2014; 273:570-579
3. Hansell DM, Goldin JG, King TE, Jr, Lynch DA, Richeldi L, Wells AU. CT staging and monitoring of fbrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner society. Lancet Respir Med 2015; 3:483-496
4. Shin KM, Lee KS, Chung M P, et al. Prognostic determinants among clinical, thin-section CT, and histopathologic fndings for fbrotic idiopathic in-terstitial pneumonias: tertiary hospital study. Radiology 2008; 249:328-337
5. Best AC, Meng J, Lynch AM, et al. Idiopathic pul-monary fbrosis: physiologic tests, quantitative CT indexes, and CT visual scores as predictors of mortality. Radiology 2008; 246:935-940
6. Gay SE, Kazerooni EA, Toews GB, et al. Idio-pathic pulmonary fbrosis: predicting response to therapy and survival. Am J Respir Crit Care Med 1998; 157:1063-1072
7. Lynch DA, Godwin JD, Safrin S, et al.; Idiopathic Pulmonary Fibrosis Study Group. High-resolution computed tomography in idiopathic pulmonary fbrosis: diagnosis and prognosis. Am J Respir Crit Care Med 2005; 172:488-493
8. Sumikawa H, Johkoh T, Colby TV, et al. Computed tomography fndings in pathological usual interstitial pneumonia: relationship to survival. Am J Respir Crit Care Med 2008; 177:433-439
9. Walsh SL, Calandriello L, Sverzellati N, Wells AU, Hansell DM; UIP Observer Consort. Interob-server agreement for the ATS/ERS/JRS/ALAT criteria for a UIP pattern on CT. Thorax 2016; 71:45-51
10. Kazerooni EA, Martinez FJ, Flint A, et al. Thin-section CT obtained at 10-mm increments versus limited three-level thin-section CT for idiopathic pulmonary fbrosis: correlation with pathologic scoring. AJR 1997; 169:977-983
11. Best AC, Lynch AM, Bozic CM, Miller D, Grunwald GK, Lynch DA. Quantitative CT indexes in idiopath-ic pulmonary fbrosis: relationship with physiologic impair ment. Radiology 2003; 228: 407-414
12. Delorme S, Keller-Reichenbecher MA, Zuna I, Schlegel W, Van Kaick G. Usual interstitial pneumonia: quantitative assessment of high-resolution computed tomography fndings by computer-as-sisted texture-based image analysis. Invest Radiol 1997; 32:566-574
13. Yoon RG, Seo JB, Kim N, et al. Quantitative as-sessment of change in regional disease patterns on serial HRCT of fbrotic interstitial pneumonia with texture-based automated quantifcation system. Eur Radiol 2013; 23:692-701
14. Maldonado F, Moua T, Rajagopalan S, et al. Automated quantifcation of radiological patterns predicts survival in idiopathic pulmonary fbrosis. Eur Respir J 2014; 43:204-212
15. Flaherty KR, Mumford JA, Murray S, et al. Prog-nostic implications of physiologic and radiograph-ic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003; 168:543-548
16. Zappala CJ, Latsi PI, Nicholson AG, et al. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary f-brosis. Eur Respir J 2010; 35:830-836
17. Richeldi L, du Bois RM, Raghu G, et al. Effcacy and safety of nintedanib in idiopathic pulmonary fbrosis. N Engl J Med 2014; 370:2071-2082
18. Noble PW, Albera C, Bradford WZ, et al.; CAPACITY Study Group. Pirfenidone in patients with idio-pathic pulmonary fbrosis (CAPACITY): two ran-domised trials. Lancet 2011; 377:1760-1769
19. King TE Jr, Albera C, Bradford WZ, et al.; IN-SPIRE Study Group. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet 2009; 374:222-228
20. King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fbrosis. N Engl J Med 2014; 370:2083-2092
21. Woodcock HV, Molyneaux PL, Maher TM. Reducing lung function decline in patients with idio-pat h ic pulmona r y fbrosis: potential of nintedanib. Drug Des Devel Ther 2013; 7:503-510
22. Song JW, Hong SB, Lim CM, Koh Y, Kim DS. Acute exacerbation of idiopathic pulmonary fbro-sis: incidence, risk factors and outcome. Eur Respir J 2011; 37:356-363
23. Miller MR, Hankinson J, Brusasco V, et al. Stan-dardisation of spirometry. Eur Respir J 2005; 26:319-338
24. Hansell DM, Bankier AA, MacMahon H, McLoud TC, Müller NL, Remy J. Fleischner Society: glossary of terms for thoracic imaging. Radiology 2008; 246:697-722
25. Park SO, Seo JB, Kim N, et al. Feasibility of auto-mated quantifcation of regional disease patterns depicted on high-resolution computed tomography in patients with various diffuse lung diseases. Korean J Radiol 2009; 10:455-463
26. Park SO, Seo JB, Kim N, Lee YK, Lee J, Kim DS. Comparison of usual interstitial pneumonia and nonspecifc interstitial pneumonia: quantifcation of disease severity and discrimination between two diseases on HRCT using a texture-based automated system. Korean J Radiol 2011; 12:297-307
27. Chang Y, Lim J, Kim N, Seo JB, Lynch DA. A support vector machine classifer reduces inter-scanner variation in the HRCT classifcation of regional disease pattern in diffuse lung disease: comparison to a Bayesian classifer. Med Phys 2013; 40:051912
28. Xaubet A, Agusti C, Luburich P, et al. Pulmonary function tests and CT scan in the management of idiopathic pulmonary fbrosis. Am J Respir Crit Care Med 1998; 158:431-436
29. Kim HJ, Brown MS, Chong D, et al. Comparison of the quantitative CT imaging biomarkers of id-iopathic pulmonary fbrosis at baseline and early change with an interval of 7 months. Acad Radiol 2015; 22:70-80
30. Wells AU, Desai SR, Rubens MB, et al. Idiopathic pulmonar y fbrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med 2003; 167:962-969
31. Reichmann WM, Yu YF, Macaulay D, Wu EQ, Nathan SD. Change in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fbrosis. BMC Pulm Med 2015; 15:167
32. Behr J. A small change in FVC but a big change for IPF: defning the minimal clinically important difference. Am J Respir Crit Care Med 2011; 184:1329-1330
33. Tashkin D P, Elashoff R, Clements PJ, et al. Cyclo-phosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354:2655-2666